Market Overview

UPDATE: JP Morgan Maintains Integra LifeSciences at Neutral Following Model Update

Share:
Related IART
Strong Top And Bottom Line Growth Expected From Integra
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed

JP Morgan reiterated its Neutral rating and $43 price target on Integra LifeSciences (NASDAQ: IART).

JP Morgan commented, "For 2013, we continue to expect adjusted EPS of $3.14 (+1.3%) on total revenues of $878.1M (+5.5%). Excluding the impact of the medical device excise tax (~$0.29), earnings growth is projected at 10.7%. By division, we project Neuro growth of 4.0%, Orthopedics growth of 7.4%, and Instruments growth of (3.9%). Longer term, we see Integra as a 5-6% and 10-11% top- and bottom-line grower, respectively. This compares to management's long-term guidance ranges of 5-7% and 9-13%. For 2014, we model adjusted EPS of $3.48 (+11.2%) on total revenues of $925.6M (+5.4%)."

Integra LifeSciences closed at $38.78 on Wednesday.

Latest Ratings for IART

DateFirmActionFromTo
Sep 2016Argus ResearchMaintainsBuy
Jul 2016JefferiesMaintainsBuy
Jul 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (IART)

View Comments and Join the Discussion!